EMA approves label update for Takeda’s HYQVIA, expands use to treat secondary immunodeficiencies
It was based on evidence from clinical trials that demonstrated that subcutaneous administration of immunoglobulin has been shown…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.